Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

NCT02261714 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer, Resected

Interventions

BIOLOGICAL: TG01
BIOLOGICAL: TG01

Sponsor

Targovax ASA